CD1D and neoplasm: Unlike conventional T cells that recognize peptide antigens presented by polymorphic MHC molecules, iNKT cells respond to lipid antigens bound to the non-polymorphic CD1d molecule, giving them a unique advantage in targeting tumor cells that present alternative or non-peptide antigens.